Stay updated on Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe MAGIC-8 study record is now available, describing a completed trial of nivolumab with or without BMS-986253 and intermittent androgen-deprivation therapy for hormone-sensitive prostate cancer. The record includes study design, participant criteria, locations, outcome measures, and a study protocol document.SummaryDifference58%

- Check15 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedAn NIH-wide notice about terminology changes during a transition appears above the ClinicalTrials.gov 403 error page.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer's ClinicalTrials.gov revision label changed from v3.7.0 to v3.7.1; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, indicating access is blocked while the site header and footer remain visible.SummaryDifference20%

Stay in the know with updates to Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page.